Related Experiment Video
Updated: Feb 7, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer
Magda Bahcall1, Mark M Awad1, Lynette M Sholl2
1Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Purpose:
MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquired amplification of wild-type (WT) KRAS as a molecular mechanism behind crizotinib resistance in three cases of METex14-mutant NSCLC and propose a combination therapy to target it.
Experimental Design:
The patient-derived cell line and xenograft (PDX) DFCI358 were established from a crizotinib-resistant METex14-mutant patient tumor with massive focal amplification of WT KRAS. To characterize the mechanism of KRAS-mediated resistance, molecular signaling was analyzed in the parental cell line and its KRAS siRNA-transfected derivative. Sensitivity of the cell line to ligand stimulation was assessed and KRAS-dependent expression of EGFR ligands was quantified. Drug combinations were screened for efficacy in vivo and in vitro using viability and apoptotic assays.
Results:
KRAS amplification is a recurrent genetic event in crizotinib-resistant METex14-mutant NSCLC. The key characteristics of this genetic signature include uncoupling MET from downstream effectors, relative insensitivity to dual MET/MEK inhibition due to compensatory induction of PI3K signaling, KRAS-induced expression of EGFR ligands and hypersensitivity to ligand-dependent and independent activation, and reliance on PI3K signaling upon MET inhibition.
Conclusions:
Using patient-derived cell line and xenografts, we characterize the mechanism of crizotinib resistance mediated by KRAS amplification in METex14-mutant NSCLC and demonstrate the superior efficacy of the dual MET/PI3K inhibition as a therapeutic strategy addressing this resistance mechanism.
Insights
Acquired KRAS amplification drives crizotinib resistance in MET exon 14 mutant NSCLC. Dual MET/PI3K inhibition effectively overcomes this resistance, offering a promising therapeutic strategy for non-small cell lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MET inhibitors are effective for MET exon 14 mutant non-small cell lung cancer (NSCLC).
- Drug resistance limits long-term efficacy of MET inhibitors.
- Acquired KRAS amplification is an emerging mechanism of resistance.
Purpose of the Study:
- Characterize acquired wild-type KRAS amplification as a mechanism of crizotinib resistance in MET exon 14 mutant NSCLC.
- Investigate the molecular signaling pathways involved in KRAS-mediated resistance.
- Propose and evaluate a combination therapy to overcome crizotinib resistance.
Main Methods:
- Established patient-derived cell line and xenograft (PDX) models from crizotinib-resistant tumors.
- Analyzed molecular signaling in parental and KRAS-silenced cell lines.
- Assessed sensitivity to ligand stimulation and quantified EGFR ligand expression.
- Screened drug combinations for efficacy in vitro and in vivo.
Main Results:
- KRAS amplification is a recurrent event in crizotinib-resistant MET exon 14 mutant NSCLC.
- KRAS amplification uncouples MET from downstream effectors and induces PI3K signaling.
- Resistance involves hypersensitivity to EGFR ligand activation and reliance on PI3K signaling.
- Dual MET/PI3K inhibition showed superior efficacy in preclinical models.
Conclusions:
- Acquired KRAS amplification is a key mechanism of crizotinib resistance in MET exon 14 mutant NSCLC.
- Dual MET/PI3K inhibition is a potential therapeutic strategy to overcome this resistance.
- Targeting KRAS-mediated resistance pathways may improve outcomes for NSCLC patients.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Treatment Resistant Cancers
Lung Capacity
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Resistivity
Resistance